DAVID M MOTT Insider Trading $ADAP Adaptimmune Therapeutics PLC
Get free email notifications about insider trading for DAVID M MOTT.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of DAVID M MOTT. DAVID M MOTT is Vice Chairman and CEO in MEDIMMUNE INC /DE ($MEDI) and Director in NOVAVAX INC ($NVAX) and 10% Owner in ARCA biopharma, Inc. ($ABIO) and 10% Owner in INTERLEUKIN GENETICS INC ($ILIU) and 10% Owner in Achaogen Inc ($AKAO) and 10% Owner in AVEO PHARMACEUTICALS INC ($AVEO) and 10% Owner in MULESOFT, INC ($MULE) and 10% Owner in Tracon Pharmaceuticals, Inc. ($TCON) and 10% Owner in Cascadian Therapeutics, Inc. ($CASC) and 10% Owner in Care.com Inc ($CRCM) and Director in ARDELYX, INC. ($ARDX) and 10% Owner in APPIAN CORP ($APPN) and Director in Mersana Therapeutics, Inc. ($MRSN) and 10% Owner in GENOCEA BIOSCIENCES, INC. ($GNCA) and 10% Owner in Roka BioScience, Inc. ($ROKA) and 10% Owner in Ra Pharmaceuticals, Inc. ($RARX) and Director in TESARO, Inc. ($TSRO) and 10% Owner in Regulus Therapeutics Inc. ($RGLS) and 10% Owner in Mirna Therapeutics, Inc. ($MIRN) and 10% Owner in Cerecor Inc. ($CERC) and 10% Owner in Trevi Therapeutics, Inc. ($TRVI) and Director in Epizyme, Inc. ($EPZM) and Director in Adaptimmune Therapeutics PLC ($ADAP) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in IMARA Inc. ($IMRA) and 10% Owner in Elastic N.V. ($ESTC) and Director in Nightstar Therapeutics plc ($NITE) and 10% Owner in Surface Oncology, Inc. ($SURF) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM).
DAVID M MOTT in Adaptimmune Therapeutics PLC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of DAVID M MOTT: Director
Holdings: 19,500,000 shares
Current Value: $88,335,000
Latest Transaction: Jul 01 2020
$ADAP Market Capitalization: $321.36M
$ADAP Previous Close: $4.53
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of DAVID M MOTT in Adaptimmune Therapeutics PLC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AKAO, ADAP, APPN, ABIO, ARDX, AVEO, CRCM, CASC, CERC, ESTC, EPZM, GNCA, IMRA, ILIU, MEDI, MRSN, MIRM, MULE, NITE, NVAX, RARX, RGLS, RYTM, ROKA, SURF, SYBX, TSRO, TCON, TRVI
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 01 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 1.67 | 226,753 | 378,678 | 226,753 | |
| Jan 28 2020 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | 12 M to 19.5 M (+62.50 %) |
| Jul 03 2019 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 0.61 | 350,947 | 214,078 | 350,947 | |
| Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 12,000,000 | 20,000,400 | 12,000,000 | 0 to 12 M |
| Sep 10 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
| Jun 26 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 2.18 | 187,330 | 408,379 | 187,330 | |
| Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
| Mar 28 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
| Jul 03 2017 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 0.75 | 302,561 | 226,921 | 302,561 | |
| Mar 28 2017 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Buy | P | 0.70 | 12,870,000 | 9,009,000 | 72,139,000 | 59.3 M to 72.1 M (+21.71 %) |
| Aug 12 2016 | ADAP | Adaptimmune Therap ... | MOTT DAVID M | Director | Option Exercise | A | 1.27 | 191,410 | 243,091 | 191,410 |
Page: 1